Neurological symptoms are uncommon in patients administered sunitinib therapy; however, a few cases of dramatic neurotoxicity attributable to the development of reversible posterior leukoencephalopathy syndrome have been reported. Here, we report a case of a 71-year old woman with severe neurological symptoms occurring during sunitinib therapy for metastatic renal cell carcinoma. The clinical symptoms were typical for reversible posterior leukoencephalopathy syndrome, but there were no accompanying neuroimaging abnormalities. A Naranjo probability score of 3 indicates the adverse drug reaction was possible, but we discuss other potential causes of this event.
MotzerRJHutsonTETomczakP. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007; 356: 115–124.
2.
EscudierBRoigasJGillessenS. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol2009; 27: 4068–4075.
3.
MendelDBLairdADXinX. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmatokinetic/pharmacodynamic relationship. Clin Cancer Res2003; 9: 327–337.
4.
GrünwaldVKalanovicDMerseburgerAS. Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World J Urol2010; 28: 343–351.
5.
KapiteijnEBrandAKroepJ. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol2007; 18: 1745–1747.
ChenAAgarwalN. Reversible posterior leucoencephalopathy syndrome associated with sunitinib. Intern Med J2009; 39: 341–342.
9.
MedioniJCojocarasuOBanuE. Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol2007; 2: 193–195.
10.
PadhyBMShanmugamSPGuptaYK. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol2011; 71: 777–779.
11.
Common Terminology Criteria for Adverse Events v4,0 (CTCAE). Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, http://ctep.cancer.gov/reporting/ctc.html (2009, accessed 29 May 2012).
12.
HincheyJChavesCAppignaniB. A reversible posterior leukoencephalopathy syndrome. N Engl J Med1996; 334: 494–500.
13.
PedrazaRMarikPEVaronJ. Posterior reversible encephalopathy syndrome. A Review. Crit Care & Shock2009; 12: 135–143.
14.
BartynskiWSBoardmanJF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol2007; 28: 1320–1327.
15.
PrasadNGulatiSGuptaRK. Spectrum of radiological changes in hypertensive children with reversible posterior leucoencephalopathy. The British J Radiol2007; 80: 422–429.
